Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

O'Hear C, Heiber JF, Schubert I, Fey G, Geiger TL.

Haematologica. 2015 Mar;100(3):336-44. doi: 10.3324/haematol.2014.112748. Epub 2014 Dec 5.

2.

Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions.

Heiber JF, Geiger TL.

Cell Immunol. 2012 Sep;279(1):60-5. doi: 10.1016/j.cellimm.2012.09.009. Epub 2012 Oct 1. Review.

3.

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Heiber JF, Xu XX, Barber GN.

Chin J Cancer. 2011 Dec;30(12):805-14. doi: 10.5732/cjc.011.10205. Epub 2011 Nov 4. Review.

4.

Evaluation of innate immune signaling pathways in transformed cells.

Heiber JF, Barber GN.

Methods Mol Biol. 2012;797:217-38. doi: 10.1007/978-1-61779-340-0_15. Review.

PMID:
21948479
5.

Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Heiber JF, Barber GN.

J Virol. 2011 Oct;85(20):10440-50. doi: 10.1128/JVI.05408-11. Epub 2011 Aug 3.

6.

The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus.

Elsby R, Heiber JF, Reid P, Kimball SR, Pavitt GD, Barber GN.

J Virol. 2011 Oct;85(19):9716-25. doi: 10.1128/JVI.05146-11. Epub 2011 Jul 27.

7.

Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.

Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX.

Gynecol Oncol. 2010 Feb;116(2):269-75. doi: 10.1016/j.ygyno.2009.10.086. Epub 2009 Nov 22.

Supplemental Content

Loading ...
Support Center